References
- Desnick RJ, Balwani M. The porphyrias. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison’s principles of internal medicine. 18th ed. New York: McGraw Hill Medical; 2012:3167–81
- Anderson KE. The porphrias. In: Goldman L, Bennett JC, Drazen JM, Gill GN, Criggs RC, Kokko JP, Mandell GL, et al., eds. Cecil’ textbook of medicine. 21st ed. Philadelphia, PA: W.S. Saunders Company; 1996:1123–30
- Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. BMJ 2000;320:1647–51
- Siegesmund M, van Tuyll van Serooskerken AM, Poblete-Gutiérrez P, Frank J. The acute hepatic porphyrias: current status and future challenges. Best Pract Res Clin Gastroenterol 2010;24:593–605
- Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000;248:319–25
- Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand) 2009;55:66–71
- Kavukçu S, Türkmen M, Saatçi O, Başdemir G, Gülay Z, Cevik NT. Juvenile rheumatoid arthritis and renal amyloidosis (case report). Int Urol Nephrol 1995;27:251–6
- Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994;37:1804–11
- Immonen K, Kauppi M, Hakala M. Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis. Scand J Rheumatol 2011;40:236–8
- Anderson CJ, Gregory MC, Groggel GC, Clegg DO. Amyloidosis and Reiter’s syndrome: report of a case and review of the literature. Am J Kidney Dis 1989;14:319–23
- McMahan ZH, Sailors JL, Toto R, Olsen NJ. Systemic amyloidosis presenting as chronic diarrhea in a patient with ankylosing spondylitis. J Clin Rheumatol 2010;16:22–5